Rocuronium requirements on the Paediatric Intensive Care Unit: the value of monitoring neuromuscular function

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN71688724

Enrollment

Registered

2004-09-30

Start date

2002-06-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nervous System Diseases: Neuromuscular function Nervous System Diseases Neuromuscular function

Interventions

Patients randomly allocated to received either standard management of NMBD (neuromuscular blocking drug) administration or protocol driven according to monitored neuromuscular function.

Eligibility

Inclusion criteria

Inclusion criteria: 30 patients under the age of 16 years requiring administration of Rocuronium to facilitate mechanical ventilation for more than 48 hours.

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

Measure	Time frame
1. Total amount of NMBD administered 2. Speed of recovery or neuromuscular function once NMBDs stopped 3. Complications related to residual NM paralysis	—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026